Nurix Therapeutics discontinued further clinical development of NX-2127, or zelebrudomide, a dual BTK and IKZF1/3 degrader for B-cell malignancies. Patients already receiving the drug may continue while clinically appropriate, with essential safety monitoring and…
Nurix Therapeutics enrolled the first participant in DAYBreak CLL-306, a global randomized Phase III trial comparing the BTK degrader bexobrutideg with pirtobrutinib in relapsed or refractory CLL/SLL after progression on a covalent BTK inhibitor….
Nurix and Roche closed their global bexobrutideg collaboration after the Hart-Scott-Rodino waiting period expired. Closing converts a previously announced agreement into an operative partnership and triggers a $700 million upfront payment, with up to…
Nurix and Roche announced a global collaboration for bexobrutideg, a potential best-in-class BTK degrader across hematology and immunology.
